STOCK TITAN

Penumbra Inc Stock Price, News & Analysis

PEN NYSE

Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.

Penumbra Inc. (NYSE: PEN) delivers innovative medical technologies transforming vascular intervention worldwide. This news hub provides investors and healthcare professionals with essential updates on the company's thrombectomy systems, regulatory milestones, and market strategies.

Access real-time press releases covering product approvals, clinical trial results, and financial performance. Our curated news collection includes analysis of Penumbra's neurovascular devices, partnership announcements, and global expansion initiatives.

Key updates feature developments in computer-assisted vacuum thrombectomy (CAVT) technology, peripheral vascular solutions, and quality improvement initiatives. Stay informed about Penumbra's progress in addressing ischemic stroke, pulmonary embolism, and other critical vascular conditions.

Bookmark this page for verified updates on Penumbra's operational achievements and industry leadership. Check regularly for insights into how the company's medical devices continue shaping modern interventional therapies across 100+ countries.

Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) will present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 11:00am ET / 8:00am PT. The event will showcase the company's innovative healthcare therapies aimed at addressing significant medical needs. Interested parties can access a webcast of the presentation via the investors' section of Penumbra's website, available for two weeks post-event. Penumbra operates primarily in the US, Europe, Canada, and Australia, focusing on cutting-edge products in the healthcare sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
-
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) has scheduled a conference call to discuss its second quarter 2021 financial results on August 9, 2021, at 4:30 PM ET. A press release with detailed financial results will be issued after the market closes on the same day. Interested parties can access the call by dialing (833) 350-1434 or through a webcast available on the company's website. Penumbra is focused on developing innovative therapies to address significant medical needs globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
-
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) announces FDA 510(k) clearance and commercial availability of the RED 62 Reperfusion Catheter, enhancing treatment capabilities for acute ischemic stroke patients. Designed for complex distal vessel anatomy, RED 62 provides powerful aspiration to effectively remove blood clots. Medical professionals praised its responsiveness and effectiveness. This launch expands the Penumbra System® portfolio and aims to reduce healthcare costs while improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) will present at the William Blair 41st Annual Growth Stock Virtual Conference on June 1, 2021, at 4:20 PM ET. The presentation can be accessed via the investor section of their website, with a recorded webcast available for two weeks post-event.

Based in Alameda, California, Penumbra specializes in innovative healthcare therapies and markets its products across the U.S., Europe, Canada, and Australia, targeting unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
-
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) reported a 23.2% increase in revenue for Q1 2021, totaling $169.2 million compared to $137.3 million in Q1 2020. Revenue from vascular products surged 50.5%, reaching $89.2 million, while neuro products saw a modest 2.5% growth to $80 million. Gross profit improved to 65.8% of total revenue. Operating expenses rose to $97.9 million, but the operating income increased significantly to $13.5 million. The company boosted its full-year revenue guidance to $695 million to $705 million, indicating a growth of 24% to 26%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
-
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) announced its management will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 11:45 am ET. A webcast of this presentation will be available on the company’s website for at least two weeks post-event. As a global healthcare company, Penumbra focuses on innovating therapies and has a broad portfolio addressing significant medical conditions. Interested parties can access the webcast via www.penumbrainc.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
conferences
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) has announced a conference call to discuss its financial results for Q1 2021, scheduled for May 4, 2021, at 4:30 PM ET. The results will be released after market close on the same day. Investors can join the call by dialing (833) 350-1434 or accessing the webcast on the company’s website. Further information about Penumbra, a global healthcare company focused on innovative therapies, can be found on its website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
-
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) has launched the Indigo® System Lightning™ 7, enhancing its Indigo Aspiration System for arterial thrombus removal. This new device combines the CAT™7 Aspiration Catheter with Lightning Intelligent Aspiration technology, enabling effective single-session clot extraction. Key features include optimized thrombus detection and reduced blood loss. CEO Adam Elsesser emphasized the technology's potential to improve patient outcomes and reduce ICU demands. The Indigo System is indicated for treating fresh emboli and thrombi in peripheral vessels and pulmonary embolism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) reported its fourth quarter and full-year financial results for 2020, revealing a 14.9% increase in quarterly revenue to $166.9 million and a full-year revenue of $560.4 million, up 2.4% year-over-year. Excluding a voluntary recall, quarterly revenue was $172.7 million, an 18.9% rise. However, a 6.6% decline in neuro product sales was noted. Operating loss for the fourth quarter stood at $1.7 million, but excluding one-time impacts, non-GAAP operating income was $16.6 million. For 2021, Penumbra projects revenue growth of 20% to 22%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
Rhea-AI Summary

Penumbra, Inc. (NYSE: PEN) announced its management team will present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 24, 2021, at 3:20 PM ET. The event aims to showcase innovative therapies and products developed by Penumbra.

A webcast of the presentation will be accessible on their website for at least two weeks post-event. Penumbra, headquartered in Alameda, California, specializes in innovative medical solutions, catering to significant unmet healthcare needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
conferences

FAQ

What is the current stock price of Penumbra (PEN)?

The current stock price of Penumbra (PEN) is $256.87 as of June 20, 2025.

What is the market cap of Penumbra (PEN)?

The market cap of Penumbra (PEN) is approximately 9.8B.
Penumbra Inc

NYSE:PEN

PEN Rankings

PEN Stock Data

9.81B
37.36M
3.93%
92.35%
3.52%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ALAMEDA